# US 9,775,886 B2 · Human placental collagen compositions, and methods of making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,775,886 B2
- Document ID: US9775886B2
- Status: Granted
- Kind: B2
- Application number: 13/610,375
- Filed: 2012-09-11
- Published: 2013-03-21
- Granted: 2017-10-03
- Earliest claimed: 2006-10-06
- Assignees: Celularity Inc.
- Applicants: Mohit Bhatia; Chris Lugo; Qian Ye; James W. Edinger
- Inventors: Mohit Bhatia; Chris Lugo; Qian Ye; James W. Edinger
- Web page: https://patentgrep.com/patent/US9775886B2

## CPC

- A61K 8/65: Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/08: Anti-ageing preparations
- C07K 1/02: in solution {(C07K1/003, C07K1/006 take precedence)}
- C07K 1/34: by filtration, ultrafiltration or reverse osmosis
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- G02B 6/12004: {Combinations of two or more optical elements}
- G02B 6/122: Basic optical elements, e.g. light-guiding paths
- G02B 6/1228: {Tapered waveguides, e.g. integrated spot-size transformers (for coupling with fibres G02B6/305)}
- G02B 6/124: Geodesic lenses or integrated gratings
- H01S 5/0064: {Anti-reflection components, e.g. optical isolators}
- H01S 5/026: Monolithically integrated components, e.g. waveguides, monitoring photo-detectors, drivers (stabilisation of output H01S5/06)
- H01S 5/1032: {Coupling to elements comprising an optical axis that is not aligned with the optical axis of the active region}
- H01S 5/187: using Bragg reflection
- H01S 5/22: having a ridge or stripe structure
- H01S 5/3013: {AIIIBV compounds}
- A61K 2800/92: Oral administration
- G02B 6/2746: {comprising non-reciprocal devices, e.g. isolators, FRM, circulators, quasi-isolators (magneto-optic non-reciprocal devices G02F1/093)}
- G02B 2006/12147: {Coupler}
- H01S 5/02326: Arrangements for relative positioning of laser diodes and optical components, e.g. grooves in the mount to fix optical fibres or lenses
- H01S 5/1035: {Forward coupled structures [DFC]}
- H01S 5/125: Distributed Bragg reflector [DBR] lasers
- H01S 5/2027: {Reflecting region or layer, parallel to the active layer, e.g. to modify propagation of the mode in the laser or to influence transverse modes}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G02B: OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- H01S: DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL

## Abstract

The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.

## Claims

### Claim 1

A composition comprising placental extracellular matrix, wherein said composition comprises at least 80% collagen by dry weight, wherein said collagen comprises (i) between 74% and 90% Type I collagen, between 4% to 6% Type III collagen, and between 2% to 15% type IV collagen, (ii) no detectable amounts of fibronectin or laminin, and (iii) additional extracellular matrix components selected from the following groups:
(a) 4.7% elastin by dry weight and 0.28% glycosaminoglycans by dry weight;
(b) 3.2% elastin by dry weight and 0.34% glycosaminoglycans by dry weight;
(c) 4.4% elastin by dry weight and 0.38% glycosaminoglycans by dry weight; and
(d) 3.5% elastin by dry weight and 0.59% glycosaminoglycans by dry weight.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said placental collagen is human placental collagen.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said composition is shaped as a sheet.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said composition is shaped to fit to a site of a wound or injury.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said composition is formulated as a gel, a cream, a paste, a spray, an aerosol, or a solution.

### Claim 6 (depends on 1)

The composition of claim 1, wherein said composition comprises a pharmacologically active agent.

### Claim 7 (depends on 6)

The composition of claim 6, wherein said pharmacologically active agent comprises platelet-derived growth factor, insulin-like growth factor, epidermal growth factor, transforming growth factor beta, an angiogenesis factor, an antibiotic, an antifungal agent, a spermicidal agent, a hormone, an enzyme, or an enzyme inhibitor.

### Claim 8 (depends on 1)

The composition of claim 1, wherein said composition is prepared by performing the following steps, in order:
a. macerating placental tissue;
b. suspending the tissue in an osmotic shock solution;
c. suspending the tissue in a solution that comprises detergent; and
d. washing the tissue.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the composition further comprises placental stem cells that are allogeneic to the subject.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the composition further comprises placental stem cells that are autologous to the subject.

### Claim 11 (depends on 8)

The composition of claim 8, wherein the detergent comprises deoxycholate.

### Claim 12 (depends on 1)

A method of treating a wound or burn of a subject comprising contacting the wound or burn with the composition of claim 1.

### Claim 13 (depends on 12)

The method of claim 12, wherein said composition is used as a wound filler.

### Claim 14 (depends on 12)

The method of claim 12, wherein said composition is applied directly to the site of the wound or burn.

### Claim 15 (depends on 1)

A method of augmenting the skin of a subject in an area of the subject in need of augmenting, wherein said method comprises administering the composition of claim 1 to said area.

### Claim 16 (depends on 15)

The method of claim 15, wherein said composition is administered by injection.

### Claim 17 (depends on 15)

The method of claim 15, wherein said composition is administered to augment skin that requires augmentation as a result aging, trauma, disease, sickness, environmental factors, weight loss, or child birth.

### Claim 18 (depends on 15)

The method of claim 15, wherein said composition is administered to augment skin that comprises wrinkles, frown lines, worry lines, crow's feet, marionette lines, stretch marks, or scars.